Eppendorf North America is now a sponsor of LabCentral, a shared laboratory space designed to be a catalyst for entrepreneurs and life science startups. The 27,000 square-foot facility is slated for opening November 1, 2013, and will be located at Kendall Square, Cambridge, MA, in the Cambridge Biotech Innovation Hub.
LabCentral received a $5 million grant from the Massachusetts Life Science Center in February of 2013. Triumvirate Environmental and Johnson & Johnson Innovation became founding sponsors shortly thereafter, and Edwards Wildman Palmer joined as a platinum sponsor. Gold sponsors include Novartis Institutes for Biomedical Research, Cushman & Wakefield, and Cooley. MIT Investment Management is LabCentral's real estate partner.
LabCentral, which aims to house as many as 25 life sciences startups employing 70+ high-potential scientists and entrepreneurs, began reviewing applications from scientists, entrepreneurs, and life science startups in July; it has reportedly accepted 12 companies to date.
"Eppendorf has a long tradition of supporting scientists in their work with best-in-class products and support," Matin Khajooei, president and CEO of Eppendorf North America, said in a statement. "LabCentral's model is unique and will change the way biotechnology companies are built in the future."
This article was reprinted from Genetic Engineering & Biotechnology News (GEN) with permission from Mary Ann Liebert, Inc., publishers. Genetic Engineering & Biotechnology News (GEN) has retained its position as the number one biotech publisher around the globe since its launch in 1981. GEN publishes a print edition 21 times a year and has additional exclusive editorial content online, like news and analysis as well as blogs, podcasts, webinars, polls, videos, and application notes. GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.